MX2023004924A - Nuevo tratamiento de la atrofia muscular espinal (sma). - Google Patents

Nuevo tratamiento de la atrofia muscular espinal (sma).

Info

Publication number
MX2023004924A
MX2023004924A MX2023004924A MX2023004924A MX2023004924A MX 2023004924 A MX2023004924 A MX 2023004924A MX 2023004924 A MX2023004924 A MX 2023004924A MX 2023004924 A MX2023004924 A MX 2023004924A MX 2023004924 A MX2023004924 A MX 2023004924A
Authority
MX
Mexico
Prior art keywords
sma
treatment
new treatment
dimethylimidazo
diazaspiro
Prior art date
Application number
MX2023004924A
Other languages
English (en)
Inventor
Jean-Paul Pfefen
Heidemarie Kletzl
Lutz Mueller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023004924A publication Critical patent/MX2023004924A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

La presente invención se refiere a 7-(4,7-diazaspiro[2.5]octan-7-i l)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimi din-4-ona para usarse en el tratamiento de la atrofia muscular espinal (SMA), a su composición farmacéutica para ser usada en el tratamiento de la SMA y a métodos de tratamiento de tal enfermedad con la misma.
MX2023004924A 2017-10-03 2020-07-13 Nuevo tratamiento de la atrofia muscular espinal (sma). MX2023004924A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17194520 2017-10-03

Publications (1)

Publication Number Publication Date
MX2023004924A true MX2023004924A (es) 2023-05-17

Family

ID=60019743

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003416A MX2020003416A (es) 2017-10-03 2018-10-01 Nuevo tratamiento de la atrofia muscular espinal (sma).
MX2023004924A MX2023004924A (es) 2017-10-03 2020-07-13 Nuevo tratamiento de la atrofia muscular espinal (sma).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003416A MX2020003416A (es) 2017-10-03 2018-10-01 Nuevo tratamiento de la atrofia muscular espinal (sma).

Country Status (11)

Country Link
US (2) US11534444B2 (es)
EP (1) EP3691647A1 (es)
JP (2) JP7423515B2 (es)
KR (1) KR20200065025A (es)
CN (2) CN117919251A (es)
AU (1) AU2018344402A1 (es)
CA (1) CA3078137A1 (es)
IL (1) IL273543A (es)
MX (2) MX2020003416A (es)
TW (1) TW201924684A (es)
WO (1) WO2019068604A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966219A (zh) * 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Sma的新治疗方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3143025B1 (en) * 2014-05-15 2019-10-09 F. Hoffmann-La Roche AG Compounds for treating spinal muscular atrophy
CA2996657A1 (en) * 2015-11-12 2017-05-18 Kathleen Dorothy MCCARTHY Compounds for treating amyotrophic lateral sclerosis
MX2018005890A (es) * 2015-11-12 2018-08-15 Hoffmann La Roche Composiciones para tratar atrofia muscular espinal.

Also Published As

Publication number Publication date
JP2020536090A (ja) 2020-12-10
US20230338382A1 (en) 2023-10-26
JP7481593B2 (ja) 2024-05-10
AU2018344402A1 (en) 2020-04-09
JP7423515B2 (ja) 2024-01-29
US11534444B2 (en) 2022-12-27
US20200375993A1 (en) 2020-12-03
JP2024041949A (ja) 2024-03-27
KR20200065025A (ko) 2020-06-08
CN117919251A (zh) 2024-04-26
EP3691647A1 (en) 2020-08-12
WO2019068604A1 (en) 2019-04-11
TW201924684A (zh) 2019-07-01
CN111182900A (zh) 2020-05-19
CA3078137A1 (en) 2019-04-11
IL273543A (en) 2020-05-31
MX2020003416A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
HK1255028A1 (zh) 4-氨基-2-(1h-吡唑並[3，4-b]吡啶-3-基)-6-氧代-6，7-二氫-5h-吡咯並[2，3-d]嘧啶衍生物及其相應的(1h-吲唑-3-基)衍生物作為治療心血管疾病的cgmp調節劑
WO2018033853A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
IL273268A (en) Process for the preparation of 7-(7,4-diazespiro[2.5]octan-7-yl)-2-(8,2-dimethylimidazo[2,1-B]pyridazin-6-yl)pyrido[2,1-A] pyrimidine-4-one
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
IL241573B (en) Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs
PH12016502115B1 (en) 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
PT3838274T (pt) Derivado de pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalina para utilização no tratamento de distúrbios do snc
MX352831B (es) Cristales de sal.
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
IL262698B (en) [1,2-b]Amidazo-converted pyridazines, [1,5-b]imidazo-converted pyridazines, related compounds and their use for the treatment of medical disorders
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
WO2017103670A8 (en) 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
EP3546460A4 (en) PYRIMIDO [5,4-B] INDOLIZIN OR PYRIMIDO [5,4-B] PYRROLIZIN COMPOUND, PRODUCTION METHOD AND USE THEREOF
EP3250208A4 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
HK1254809A1 (zh) 治療中有用的吡唑並[1，5-a]三嗪-4-胺衍生物
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2015017972A (es) Cristales de base libre.
IL251107B (en) History of [2h]-imidazo-[1,2-a]pyrazolo[3,4-e]pyrimidine-4(5h)-one, pharmaceutical preparations containing them and their use in disorders of the central nervous system.
MX2015000336A (es) Inhibidores de la enzima fosfodiesterasa 10.
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
HK1206250A1 (en) Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders pde2 1--4--[124][43-a]- pde10
EP3344625A4 (en) THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders